Drug Trial Radar · NCT06144840
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Dec 11, 2023
Primary completion
Apr 14, 2026
Study completion May 19, 2026
Sponsor
- Lead sponsor
- Tanabe Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Conditions
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
Interventions
DersimelagonDrug
MT-7117
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at Week 16Time frame: Week 16
Locations
35 sites in 11 countries. Site status is shown where the registry gives one.
Marvel Clinical Research, LLC
Huntington Beach, California
University of California at San Francisco
San Francisco, California
University Of Miami School Of Medicine, Center For Liver Diseases
Miami, Florida
MGH
Boston, Massachusetts
MetroBoston Clinical Partners, LLC
Brighton, Massachusetts
Henry Ford Health System
Detroit, Michigan
Kansas City Research Institute
Kansas City, Missouri
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York
Wake Forest University Baptist Health
Winston-Salem, North Carolina
Remington-Davis Clinical Research
Columbus, Ohio
Einstein Medical Center (EMC)
Philadelphia, Pennsylvania
The University of Texas Medical Branch (UTMB)
Galveston, Texas
University of Washington
Seattle, Washington
Royal Melbourne Hospital (RMH)
Parkville, Victoria, Australia
University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski - Porphyria Center
Sofia, Bulgaria
Institute for Clinical and Experimental Medicine - IKEM
Prague, Czechia
Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre
Bordeaux, France
CHU Nantes
Nantes, France
Hôpital Bichat - Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine
Paris, France
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier
Paris, France
Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
Brescia, Italy
Azienda Sanitaria Ospedaliera Santa Croce E Carle - Cuneo
Cuneo, Italy
Ospedalle Galliera
Genova, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy
U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena
Modena, Italy
IFO-San Gallicano IRCCS
Rome, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Materno-Infantile - Burlo Garofolo - Clinica Pediatrica
Trieste, Italy
Tokyo Saiseikai Central Hospital
Tokyo, Japan
Mazda Hospital
Aki-gun, Hiroshima, Japan
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan
Universitair Medisch Centrum Rotterdam
Rotterdam, Netherlands
Instytut Hematologii I Transfuzjologii
Warsaw, Poland
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital General Universitario De Valencia
Valencia, Spain
Guy's Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.